On Nov 07, major Wall Street analysts update their ratings for $Arcellx (ACLX.US)$, with price targets ranging from $91 to $120.
Morgan Stanley analyst Judah Frommer maintains with a buy rating, and adjusts the target price from $81 to $106.
Evercore analyst Cory Kasimov maintains with a buy rating, and maintains the target price at $120.
Piper Sandler analyst Biren Amin maintains with a buy rating, and adjusts the target price from $70 to $91.
Truist Financial analyst Asthika Goonewardene maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Arcellx (ACLX.US)$'s main analysts recently are as follows:
The analyst is enhancing their outlook on the potential success of anito-cel after the preliminary results from the iMMagine-1 Phase 2 trial in patients with relapsed/refractory multiple myeloma (rrMM). There is perceived to be a substantial opportunity for market share for anito-cel, initially amongst patients who have received multiple prior lines of therapy and potentially, in the future, in those who are earlier in their treatment journey, should the existing clinical profile remain consistent.
Abstracts from a recent medical conference that presented initial Phase 2 data and additional Phase 1 follow-up information have reaffirmed a pivotal-stage therapy's competitive position and regulatory prospects in the treatment of multiple myeloma. Despite a downturn in the share price, this is perceived as a reaction to recent news following a significant run-up due to abstract anticipation. It is now anticipated that the therapy will achieve a more robust peak market share and has increased chances of success.
The firm indicated a growing positive stance based on updated clinical data. This view was reinforced by the published ASH abstracts, which included initial data from the registrational IMMagine-1 study.
Here are the latest investment ratings and price targets for $Arcellx (ACLX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月7日，多家华尔街大行更新了$Arcellx (ACLX.US)$的评级，目标价介于91美元至120美元。
摩根士丹利分析师Judah Frommer维持买入评级，并将目标价从81美元上调至106美元。
Evercore分析师Cory Kasimov维持买入评级，维持目标价120美元。
派杰投资分析师Biren Amin维持买入评级，并将目标价从70美元上调至91美元。
储亿银行分析师Asthika Goonewardene维持买入评级。
此外，综合报道，$Arcellx (ACLX.US)$近期主要分析师观点如下：
分析师对anito-cel的潜在成功前景持乐观态度，基于iMMagine-1阶段2试验在复发/难治性多发性骨髓瘤（rrMM）患者中的初步结果。认为anito-cel在市场份额上存在巨大机会，首先是在已接受多种前线治疗的患者中，未来可能扩展至早期治疗中的患者，若现有临床资料保持一致。
最近医疗会议摘要呈现了初步2期数据和额外1期随访信息，重申了关键阶段治疗的竞争地位和在多发性骨髓瘤治疗中的监管前景。尽管股价出现下跌，但这被视为对最近新闻的反应，因为摘要预期大幅上升。现在预计该疗法将获得更强劲的峰值市场份额，并增加成功机会。
该公司根据更新的临床数据表明日益正面态度。这一观点得到了发表的ASH摘要的支持，其中包括注册IMMagine-1研究的初步数据。
以下为今日4位分析师对$Arcellx (ACLX.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
